<DOC>
	<DOCNO>NCT02786160</DOCNO>
	<brief_summary>The study randomise , placebo-controlled , double-blind , parallel study obese child . A total 75 obese child age 5 10 year , enrol childhood obesity treatment program , include . The participate child randomise one three group consume either HMO ( two group ) placebo ( one group ) . The primary objective study establish effect HMOs faecal microbiota child . Secondary objective evaluate safety HMO supplementation child effect gastrointestinal symptom ( tolerance ) , bowel habit , metabolic profile body composition obese child .</brief_summary>
	<brief_title>Effects HMOs Faecal Microbiota Host Metabolism Obese Children</brief_title>
	<detailed_description />
	<criteria>1 . Informed , write consent child 's representative ( ) inform verbal assent child 2 . Age ≥5 &lt; 11 year visit 0 3 . BMI SDS ≥ 2.3 4 . Enrolment childhood obesity treatment program Children 's Obesity Clinic 5 . Ability willingness understand comply study procedures 6 . The child 's representative ( ) need ( ) read , speak understand Danish 1 . Participation another clinical intervention study one month prior screen visit throughout study . 2 . Any gastrointestinal disease ( ) may cause symptom may interfere trial outcome , judge investigator . 3 . Other severe disease ( ) malignancy , kidney disease neurological disease , judge investigator . 4 . Psychiatric disease , judge investigator . 5 . Use probiotic supplement ( yoghurt allow ) 3 month prior screen throughout study . 6 . Consumption antibiotic drug 3 month prior screen throughout study . 7 . Consumption regular basis medication might interfere symptom evaluation ( judged investigator ) 2 week prior screen throughout study . 8 . Lack suitability participation study reason judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>